Skip to content

Drug interactions

Dabigatran etexilate + Lapatinib

Severity: Moderate

Dabigatran etexilate and Lapatinib: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Lapatinib inhibits intestinal P-glycoprotein and may increase absorption of dabigatran etexilate, raising dabigatran concentrations and bleeding risk. The effect is more relevant with renal impairment.

What this interaction means in plain words

Dabigatran etexilate and Lapatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Dabigatran etexilate belongs to Cardiovascular; Lapatinib belongs to Oncology.

Evidence level: Low

Why it happens

Inhibition of P-glycoprotein efflux of dabigatran etexilate in the gut.

What to do

Monitor for bleeding and renal function. Avoid the combination in patients with significantly reduced creatinine clearance.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Dabigatran etexilate and Lapatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Dabigatran etexilate with Lapatinib?

MediHelp rates the interaction as moderate. Dabigatran etexilate and Lapatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lapatinib inhibits intestinal P-glycoprotein and may increase absorption of dabigatran etexilate, raising dabigatran concentrations and bleeding risk. The effect is more relevant with renal impairment.

How serious is the interaction between Dabigatran etexilate and Lapatinib?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for bleeding and renal function. Avoid the combination in patients with significantly reduced creatinine clearance.

What other medicines interact with Dabigatran etexilate?

MediHelp also lists interactions of Dabigatran etexilate with, for example, Defibrotide, Ketorolac, Mifepristone. The full list is on the Dabigatran etexilate page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in